Feb 01, 2024
- Corporate
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2023
| Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
| Code number: | 4519 (Prime Market of Tokyo Stock Exchange) |
| Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
| President & CEO: | Osamu Okuda |
| Inquiries to: | Kae Miyata |
| Head of Corporate Communications Dept. | |
| Tel:+81-(0)3-3273-0554 |
F. Hoffmann-La Roche Ltd. (hereafter “Roche”) [Head Office: Basel, Switzerland. CEO: Thomas Schinecker] announced today its financial results for fiscal 2023 (January 1 – December 31, 2023).
Roche owns 59.89% of Chugai’s issued shares (61.13% of voting rights) as of the end of December 2023.
Its investor update and presentation materials can be found on its website (https://www.roche.com).
Chugai’s performance for the period of January 1 to December 31, 2023 is included in the announced Roche Group’s results.
| Investor Updates | Reporting |
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
